JCI Insight (Oct 2022)

Benefits of global mutant huntingtin lowering diminish over time in a Huntington’s disease mouse model

  • Deanna M. Marchionini,
  • Jeh-Ping Liu,
  • Alberto Ambesi-Impiombato,
  • Kimberly Kerker,
  • Kim Cirillo,
  • Mukesh Bansal,
  • Rich Mushlin,
  • Daniela Brunner,
  • Sylvie Ramboz,
  • Mei Kwan,
  • Kirsten Kuhlbrodt,
  • Karsten Tillack,
  • Finn Peters,
  • Leena Rauhala,
  • John Obenauer,
  • Jonathan R. Greene,
  • Christopher Hartl,
  • Vinod Khetarpal,
  • Brenda Lager,
  • Jim Rosinski,
  • Jeff Aaronson,
  • Morshed Alam,
  • Ethan Signer,
  • Ignacio Muñoz-Sanjuán,
  • David Howland,
  • Scott O. Zeitlin

Journal volume & issue
Vol. 7, no. 20

Abstract

Read online

We have developed an inducible Huntington’s disease (HD) mouse model that allows temporal control of whole-body allele-specific mutant huntingtin (mHtt) expression. We asked whether moderate global lowering of mHtt (~50%) was sufficient for long-term amelioration of HD-related deficits and, if so, whether early mHtt lowering (before measurable deficits) was required. Both early and late mHtt lowering delayed behavioral dysfunction and mHTT protein aggregation, as measured biochemically. However, long-term follow-up revealed that the benefits, in all mHtt-lowering groups, attenuated by 12 months of age. While early mHtt lowering attenuated cortical and striatal transcriptional dysregulation evaluated at 6 months of age, the benefits diminished by 12 months of age, and late mHtt lowering did not ameliorate striatal transcriptional dysregulation at 12 months of age. Only early mHtt lowering delayed the elevation in cerebrospinal fluid neurofilament light chain that we observed in our model starting at 9 months of age. As small-molecule HTT-lowering therapeutics progress to the clinic, our findings suggest that moderate mHtt lowering allows disease progression to continue, albeit at a slower rate, and could be relevant to the degree of mHTT lowering required to sustain long-term benefits in humans.

Keywords